Over the last few decades, significant progress has been made in diagnosing, understanding the pathophysiology and natural history of, and managing pancreatic neuroendocrine tumors (PanNETs). The term PanNETs encompasses a large and heterogeneous group of tumors that can be functional (ie, associated with clinical symptoms in relation to secreted peptides) or nonfunctional, sporadic, from a genetic origin, indolent in the long-term, or aggressive and life-threatening. Managing patients is highly challenging when being faced with such heterogeneous neoplasms and carcinoma. As stated by Li et al1 in their comprehensive review, an individualized approach should be the goal of treatment, given the heterogeneity of these tumors.